Janus Kinases are enzymes found in cells in the immune system that are critical for the cell signaling process. JAK inhibitors block the inflammatory signaling pathways, inhibiting the genes that trigger autoimmune processes.
The FDA has issued Boxed Warnings for one of the marketed JAK inhibitor drugs used in the comparative study.
The public was notified of serious side effects including an increased risk of blood clots in the lungs and death in rheumatoid arthritis patients taking a standard dose of the product.
In addition to JAK inhibition, MYMD-1 has shown efficacy as a selective inhibitor of TNF-α, a driver of chronic inflammation. MYMD-1 has also been shown to be effective in traversing the blood-brain barrier, a differentiator that can increase the drug's benefit to patients.
MyMD Pharmaceuticals, Inc. (NASDAQ: MYMD) is a clinical stage pharmaceutical company.
MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immunometabolic system to control TNF-α and other pro-inflammatory cytokines. MYMD-1 is being developed to treat autoimmune diseases, including those currently treated with non-selective TNF-α blocking drugs, and aging and longevity.
The company's second drug platform, Supera-CBD, is based on a novel (patent pending) synthetic derivative of cannabidiol that targets numerous key receptors including CB2 and opioid receptors and inhibits monoamine oxidase.
Supera-CBD is being developed to address the rapidly growing CBD market, that includes FDA approved drugs and CBD products not currently regulated as a drug.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML